4.16
1.89%
-0.08
Eagle Pharmaceuticals Inc stock is currently priced at $4.16, with a 24-hour trading volume of 79,461.
It has seen a -1.89% decreased in the last 24 hours and a -17.46% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.31 pivot point. If it approaches the $4.12 support level, significant changes may occur.
Previous Close:
$4.24
Open:
$4.25
24h Volume:
79,461
Market Cap:
$53.91M
Revenue:
$257.55M
Net Income/Loss:
$11.95M
P/E Ratio:
4.5714
EPS:
0.91
Net Cash Flow:
$-9.39M
1W Performance:
-9.76%
1M Performance:
-17.46%
6M Performance:
-69.52%
1Y Performance:
-84.98%
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Name
Eagle Pharmaceuticals Inc
Sector
Phone
201-326-5300
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
Nov-01-18 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Oct-31-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
Mar-21-18 | Reiterated | Mizuho | Underperform |
Nov-09-17 | Reiterated | RBC Capital Mkts | Outperform |
Sep-06-17 | Reiterated | Mizuho | Underperform |
Jul-27-17 | Reiterated | Mizuho | Underperform |
Jul-27-17 | Reiterated | RBC Capital Mkts | Outperform |
May-09-17 | Reiterated | RBC Capital Mkts | Outperform |
Jan-09-17 | Downgrade | Mizuho | Neutral → Underperform |
Nov-16-16 | Downgrade | Mizuho | Buy → Neutral |
Nov-03-16 | Upgrade | Mizuho | Neutral → Buy |
Nov-03-16 | Reiterated | RBC Capital Mkts | Outperform |
Oct-26-16 | Reiterated | Mizuho | Buy |
Aug-16-16 | Reiterated | Mizuho | Neutral |
Jun-20-16 | Downgrade | Mizuho | Buy → Neutral |
May-10-16 | Reiterated | RBC Capital Mkts | Outperform |
Mar-18-16 | Reiterated | Mizuho | Buy |
Feb-26-16 | Reiterated | Mizuho | Buy |
Dec-09-15 | Initiated | Mizuho | Buy |
Jul-29-15 | Reiterated | Piper Jaffray | Overweight |
View All
Eagle Pharmaceuticals Inc Stock (EGRX) Latest News
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
GlobeNewswire Inc.
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
GlobeNewswire Inc.
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City
GlobeNewswire Inc.
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
GlobeNewswire Inc.
Eagle Pharmaceuticals Announces Management Change
GlobeNewswire Inc.
Eagle Pharmaceuticals Inc Stock (EGRX) Financials Data
Eagle Pharmaceuticals Inc (EGRX) Revenue 2024
EGRX reported a revenue (TTM) of $257.55 million for the quarter ending June 30, 2023, a -5.38% decline year-over-year.
Eagle Pharmaceuticals Inc (EGRX) Net Income 2024
EGRX net income (TTM) was $11.95 million for the quarter ending June 30, 2023, a -47.57% decrease year-over-year.
Eagle Pharmaceuticals Inc (EGRX) Cash Flow 2024
EGRX recorded a free cash flow (TTM) of -$9.39 million for the quarter ending June 30, 2023, a -126.60% decrease year-over-year.
Eagle Pharmaceuticals Inc (EGRX) Earnings per Share 2024
EGRX earnings per share (TTM) was $0.91 for the quarter ending June 30, 2023, a -48.30% decline year-over-year.
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Cap:
|
Volume (24h):